<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141826</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-111-19</org_study_id>
    <nct_id>NCT04141826</nct_id>
  </id_info>
  <brief_title>Absorption of Peptides, Fluid, and Electrolytes in Patients With an Ileostomy</brief_title>
  <acronym>ABSOLYT</acronym>
  <official_title>Absorption of Peptides, Fluid, and Electrolytes in Patients With an Ileostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Hvas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial, active comparator, cross over, randomised. In total, 12 adults with an
      ileostomy will be randomised to a sequential 4 weeks intervention with different qualities
      and sources of protein wish 2-week washout periods. Primary outcome: Ileostomy output.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with an ileostomy may be dehydrated and have nutritional deficiencies secondary to
      malabsorption of fluid, electrolytes, and nutrients. In this randomised, double blinded,
      crossover intervention study we aim to investigate how different protein sources affect
      intestinal absorption in patients with an ileostomy and intestinal insufficiency. Three oral
      solutions with different protein sources (hydrolysed whey, whey, and casein) will be
      administered in three different four-week intervention periods. The results will facilitate
      improved counselling and treatment of patients with an ileostomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Production in separate facility, randomisation key kept by third party</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour fecal wet weight</measure>
    <time_frame>4 weeks</time_frame>
    <description>Difference in mean ileostomy output (wet weight) during 24 hours at the end of each intervention period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diuresis</measure>
    <time_frame>4 weeks</time_frame>
    <description>24 hour urine volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natriuresis</measure>
    <time_frame>4 weeks</time_frame>
    <description>24 hour urine sodium excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino acid absorption</measure>
    <time_frame>6 hours</time_frame>
    <description>Plasma amino acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric and small bowel emptying</measure>
    <time_frame>6 hours</time_frame>
    <description>3D transit evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP1 and GLP2</measure>
    <time_frame>6 hours</time_frame>
    <description>Intestinal hormones during absorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portosystemic hepatic encephalopathy (PSE) test score, median value</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pen and paper test, score with range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portosystemic hepatic encephalopathy (PSHE) test score abnormal (&lt;4)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pen and paper test, score with range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous reaction time (CRT) index median</measure>
    <time_frame>4 weeks</time_frame>
    <description>Reaction to 150 sound stimuli, read-out as index compared to normal values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Telemetric sensor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kg)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bio-impedance analysis (SECA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body water (L)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bio-impedance analysis (SECA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular water (L)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bio-impedance analysis (SECA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle mass (kg)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bio-impedance analysis (SECA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat-free mass (kg)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bio-impedance analysis (SECA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass (kg)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bio-impedance analysis (SECA)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Nutritional Deficiency</condition>
  <condition>Ileostomy; Functional Disturbance</condition>
  <condition>Short Bowel Syndrome</condition>
  <condition>Absorption; Disorder, Protein</condition>
  <arm_group>
    <arm_group_label>Hydrolysed whey</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrolysed whey</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intact whey</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intact whey</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caseinate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Caseinate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hydrolysed whey</intervention_name>
    <description>500 mL solution of 25 gram hydrolysed whey per day during 4 weeks</description>
    <arm_group_label>Hydrolysed whey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intact whey</intervention_name>
    <description>500 mL solution of 25 gram intact whey per day during 4 weeks</description>
    <arm_group_label>Intact whey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caseinate</intervention_name>
    <description>500 mL solution of 25 gram casein ate per day during 4 weeks</description>
    <arm_group_label>Caseinate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (≥ 18 years old), male or female patients with an ileostomy and intestinal
             insufficiency

          -  Episodical or chronic sodium depletion defined by two urine samples with sodium levels
             ≤ 20 mmol/L, sampled with at least 28 days apart

          -  Six months or more after most recent bowel surgery

          -  If inflammatory bowel disease, no clinical signs of activity (any treatment allowed
             except systemic steroids &gt; 10 mg/day)

        Exclusion Criteria:

          -  Parenteral nutrition or intravenous fluid support ≥ 4000 mL/month

          -  Ongoing infection (C-reactive protein above 8 mg/L or core temperature &gt;38.0°C)

          -  Self-reported intolerance to dairy products, including lactose intolerance

          -  Inability to understand Danish or the trial procedures

          -  Known or anticipated pregnancy

          -  Known severe renal insufficiency (eGFR &lt; 20 mL/min)

          -  Known diabetes mellitus (HbA1c ≥ 48 mmol/mol (6.5%))

          -  Pacemaker, cochlear implants, or other electrical implants excludes the participants
             from BIA-measurements and measurements of GITT with 3D-Transit capsules, but not the
             remaining investigations

          -  Known intestinal stenosis or parastomal hernia excludes measurements of GITT with
             3D-Transit capsules, but not the remaining investigations

          -  Abdominal diameter &gt; 140 cm, or planned MR scan four weeks following participation
             excludes measurements of GITT with 3D-Transit capsules, but not the remaining
             investigations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian L Hvas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian L Hvas, PhD</last_name>
    <phone>+4528351839</phone>
    <email>christian.hvas@auh.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Rud, MSc</last_name>
    <phone>+4578453800</phone>
    <email>charru@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian L Hvas, MD PhD</last_name>
      <phone>+45 28351839</phone>
      <email>christian.hvas@auh.rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Rud, MS</last_name>
      <email>charru@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Hvas</investigator_full_name>
    <investigator_title>Consultant, associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised data or selections herof will be shared upon specific agreements and with researchers who have legitimate causes, following contact to the PI</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>upon request, after publication</ipd_time_frame>
    <ipd_access_criteria>contact to PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

